We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+2.72%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.67B
AUM Growth
+$920K
Cap. Flow
+$82.4M
Cap. Flow %
3.09%
Top 10 Hldgs %
54.57%
Holding
76
New
9
Increased
18
Reduced
16
Closed
6

Top Buys

Rank Stock Value
1
GHRS icon
GH Research
GHRS
+$189M
2
ARGX icon
argenx
ARGX
+$97.1M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$42.5M
4
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$34.1M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$29.8M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$239M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$61.3M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$61.3M
4
CTMX icon
CytomX Therapeutics
CTMX
+$43.1M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$35.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.39%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OVID icon
26
Ovid Therapeutics
OVID
$420M
$25.9M 0.97%
6,631,051
+213,500
+3% +$843K
INFI
27
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$25.1M 0.94%
8,383,645
– –
IMA
28
ImageneBio Inc
IMA
$63.7M
$24.8M 0.93%
147,283
+13,978
+10% +$3.08M
MTEM
29
DELISTED
Molecular Templates, Inc.
MTEM
$22.3M 0.84%
190,440
-513
-0.3% -$67.1K
CTIC
30
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$22.3M 0.84%
8,929,690
+2,000,000
+29% +$4.8M
CBIO
31
Crescent Biopharma
CBIO
$527M
$22.1M 0.83%
95,443
– –
CALT
32
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$22.1M 0.83%
750,000
– –
ELEV
33
DELISTED
Elevation Oncology
ELEV
$21.6M 0.81%
+1,590,291
New +$19.7M
ANAB icon
34
AnaptysBio
ANAB
$1.56B
$21M 0.79%
808,710
-380,790
-32% -$9.13M
DAWN
35
DELISTED
Day One Biopharmaceuticals
DAWN
$20.9M 0.78%
+918,975
New +$19.2M
PVLA
36
Palvella Therapeutics
PVLA
$2.02B
$20.4M 0.76%
66,603
-2,079
-3% -$456K
FBRX icon
37
Forte Biosciences
FBRX
$1.57B
$19.9M 0.75%
23,672
-5,080
-18% -$4.58M
CGEM icon
38
Cullinan Oncology
CGEM
$1.01B
$18.9M 0.71%
735,106
-314,250
-30% -$9.66M
NGM
39
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$18.8M 0.71%
+955,000
New +$22.4M
ACRS icon
40
Aclaris Therapeutics
ACRS
$728M
$17.6M 0.66%
+1,000,000
New +$22.7M
CFRX
41
DELISTED
ContraFect Corporation
CFRX
$17.5M 0.66%
49,654
+2,000
+4% +$655K
SLN
42
Silence Therapeutics
SLN
$524M
$17M 0.64%
666,666
– –
GRTS
43
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$16.7M 0.63%
1,826,494
-34,745
-2% -$321K
STRO icon
44
Sutro Biopharma
STRO
$404M
$15.4M 0.58%
82,683
– –
CALA
45
DELISTED
Calithera Biosciences, Inc
CALA
$15.3M 0.57%
364,967
+86,632
+31% +$3.81M
ELTX icon
46
Elicio Therapeutics
ELTX
$74.3M
$13.5M 0.51%
103,650
+16,150
+18% +$2.33M
IMVT icon
47
Immunovant
IMVT
$7.89B
$13.5M 0.5%
1,273,516
+129,500
+11% +$1.81M
COGT icon
48
Cogent Biosciences
COGT
$6.7B
$12.4M 0.47%
1,532,282
– –
LITS
49
Lite Strategy Inc
LITS
$33.3M
$10.1M 0.38%
176,603
-2,805
-2% -$180K
CRVS icon
50
Corvus Pharmaceuticals
CRVS
$1.12B
$9.82M 0.37%
3,678,626
+449,200
+14% +$1.24M
1
2
3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2021 Portfolio in Review

As of Q2 2021, BVF Inc held 76 positions worth $2.67B, up 0.03% from $2.67B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

BVF Inc deployed $82.4M of net new capital in Q2 2021, opening 9 new positions and adding to 18 existing holdings. Its largest new stake was GH Research: 9,275,156 shares worth $202M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $35.2M trimmed.

  • BVF Inc's largest Q2 2021 buy was GH Research: 9,275,156 shares worth $202M.
  • BVF Inc added most to argenx in Q2 2021, an estimated $97.1M increase.
  • BVF Inc's biggest Q2 2021 reduction was Xenon Pharmaceuticals, cutting an estimated $35.2M.
  • BVF Inc fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $239M.
  • BVF Inc's ten largest holdings make up 55% of its $2.67B portfolio in Q2 2021.
  • BVF Inc opened 9 new positions and closed 6 in Q2 2021.
  • BVF Inc's portfolio value rose 0.03% quarter-over-quarter to $2.67B.

Based on BVF Inc's 13F filing for Q2 2021, filed 16 Aug 2021.